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The content of this report stems from the work published in two 
separate reports, one led by the World Economic Forum and the 
Harvard School of Public Health, and the other developed by the 
World Health Organization:
The Global Economic Burden of Non-communicable Diseases – 
prepared by the World Economic Forum and the Harvard School 
of Public Health (2011). Available through: 
http://www.weforum.org/EconomicsOfNCD
Scaling up action against noncommunicable diseases: How much 
will it cost? – prepared by the World Health Organization (2011). 
Available through: http://www.who.int/nmh/publications
This report with the overview from these two recent papers does 
not represent an official position of the World Health Organization, 
the World Economic Forum or the Harvard School of Public 
Health. It is a tool to explore the views of interested parties on the 
subject matter. The authors alone are responsible for the views 
expressed in this overview and they do not necessarily represent 
the decisions, policy or views of the World Health Organization, 
the World Economic Forum or the Harvard School of Public 
Health. References to international partners are suggestions only 
and do not constitute or imply any endorsement whatsoever of 
this overview.3
Summary
There is growing awareness and concern about the large and escalating burden of chronic, non-communicable 
diseases (NCDs) not just from the public health perspective but also from the economic one. The social burdens 
associated with the four diseases that are the focus of the UN High-Level Meeting on NCDs – cardiovascular 
disease, diabetes, cancer and chronic respiratory diseases – include prolonged disability, diminished resources 
within families and reduced productivity, in addition to tremendous demands on health systems. 
This report addresses current information gaps in our understanding of how to mitigate these challenges by 
highlighting recent findings about the social costs of NCDs and the resource needs for managing these conditions. 
Specifically, the report brings together findings from two new studies aimed at equipping decision-makers in 
government, civil society and the private sector with key economic insights needed to help reduce the growing 
burden of NCDs: 
•	 A global analysis of the economic impact of NCDs by the World Economic Forum and the Harvard School of 
Public Health
•	 An analysis of the costs of scaling up a core intervention package in low- and middle-income countries by the 
World Health Organization
The economic consequences of NCDs are staggering. Under a “business as usual” scenario where intervention 
efforts remain static and rates of NCDs continue to increase as populations grow and age, cumulative economic 
losses to low- and middle-income countries (LMICs) from the four diseases are estimated to surpass US$ 7 
trillion over the period 2011-2025 (an average of nearly US$ 500 billion per year). This yearly loss is equivalent to 
approximately 4% of these countries’ current annual output. On a per-person basis, the annual losses amount to 
an average of US $25 in low-income countries, US$ 50 in lower middle-income countries and US$ 139 in upper 
middle-income countries. 
By contrast, findings from the second study by the WHO indicate that the price tag for scaled-up implementation 
of a core set of NCD “best buy” intervention strategies is comparatively low. Population-based measures for 
reducing tobacco and harmful alcohol use, as well as unhealthy diet and physical inactivity, are estimated to cost 
US$ 2 billion per year for all LMICs – less than US$ 0.40 per person. Individual-based NCD “best buy” interventions 
– which range from counselling and drug therapy for cardiovascular disease to measures to prevent cervical cancer 
– bring the total annual cost to US$ 11.4 billion. On a per-person basis, the annual investment ranges from under 
US$ 1 in low-income countries to US$ 3 in upper middle-income countries.
In health terms, the return on this investment will be many millions of avoided premature deaths. In economic 
terms, the return will be many billions of dollars of additional output. For example, reducing the mortality rate 
for ischaemic heart disease and stroke by 10% would reduce economic losses in LMICs by an estimated US$ 
25 billion per year, which is three times greater than the investment needed for the measures to achieve these 
benefits. 
Policy-makers, members of civil society and business leaders all face the issue of how best to respond to the 
challenges posed by NCDs. This overview of two recent reports supplements existing knowledge by demonstrating 
not only the economic harm done by NCDs but also the costs and benefits related to addressing them. 4
The Economics of NCDs
Since 2009, a survey of business leaders from around the world carried out by the World Economic Forum 
identifies chronic disease as one of the leading threats to global economic growth1. Mortality and prolonged 
disability associated with NCDs have a sizeable economic impact on households, industries and societies, both via 
the consumption of health services and via losses in income, productivity and capital formation.
Specific intervention strategies can effectively tackle leading causes of NCDs and their underlying risk factors, 
as a growing body of evidence has demonstrated. These interventions include population level measures that 
encourage reduced consumption of tobacco, alcohol and salt; improved awareness of healthy life styles; increased 
excise taxes; and enhanced regulation. Individual-based interventions include the prevention and management of 
heart disease and strokes, as well as early detection and treatment of cancer. The combined cost of implementing 
these population- and individual-based measures, however, is not well established. This information gap has 
impeded the mobilization of necessary resources and planning at global and national levels. 
This report attempts to fill current information gaps in our understanding of what specific impact NCDs might have 
on economic growth and what resources are needed to mitigate this impact. It brings together findings from two 
recently completed studies that can inform international policy dialogue, including the UN High-Level Meeting on 
NCDs. Their findings shed light on:
•	 Size of the problem – Economic analysis by the World Economic Forum and the Harvard School of Public 
Health identifies the sizeable economic burden of NCDs on societies.
•	 Possible solutions and their cost – Analysis by the World Health Organization (WHO) has identified a set of 
affordable, feasible and cost-effective intervention strategies (NCD “best buys”); its newly published study 
estimates a global price tag for implementing these measures.
•	 Potential benefits of taking action – Further analysis presented in this joint report by the WHO and the World 
Economic Forum indicates how LMICs could avert millions of deaths and reduce economic losses by billions of 
dollars over the next 15 years by making renewed efforts to tackle NCDs at the population and individual level.
1 World Economic Forum (2010). Global Risks 2009: A Global Risk Network Report.
2 Abegunde, .D, Stanciole, A. “An estimation of the economic impact of chronic noncommunicable diseases in selected countries”. WHO Working Paper 
Department of Chronic Diseases and Health Promotion (CHP), 2006.
Box 1: Estimating economic losses due to ill health: The WHO EPIC tool
The EPIC tool was developed by the World Health Organization to simulate the economic impact of diseases 
on aggregate economic output2. EPIC links the value of economic output to quantities of labour and capital 
inputs, as well as to technology. The EPIC model adjusts labour and capital inputs according to population 
health. Namely, labour is diminished by disability and death caused by NCDs. Capital is also reduced because 
costs of screening, treatment and care claim resources that would otherwise be available for public and private 
investment. The EPIC model predicts losses caused by different health conditions in terms of their effect on the 
value of economic output.
NCDs 
Economic  
Output  US$ 
Capital 
Labour 5
3 The study used the 2011 World Bank classifications distinguishing lower income and middle- income countries. Middle-income countries are further 
subdivided into lower middle and upper middle, and categorization depends on a country’s gross national income per capita. The present report refers to 
low, lower middle-income and upper middle-income countries collectively as LMICs.  
For the income category of countries, please see: siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS. For example, China is currently 
classified as an upper middle-income country and India as a lower middle-income country.
4 World Development Indicators. 2010. Washington DC: World Bank.
5 The full report prepared by the World Economic Forum and the Harvard School of Public Health covers similar ground to this joint Forum-WHO report, 
except that it focuses on 2010-2030, includes mental health conditions as an NCD, implements two methodologies in addition to EPIC for estimating the 
economic burden of NCDs (Cost of Illness and Value of a Statistical Life), and provides results for high-income countries as well.
Size of the Problem: Demonstrating the Economic Burden of NCDs
The economic burden study carried out by the World Economic Forum and the Harvard School of Public Health set 
out to assess economic losses associated with NCDs. The focus of analysis in this joint report is on LMICs, which 
account for 84% of the world’s population and 83% of the non-communicable disease burden (as measured by 
DALYs (disability-adjusted life years)3. The WHO’s EPIC tool is used to quantify losses in these countries, which it 
does by relating projected NCD mortality rates in a population to current and future economic output at the national 
level (see Box 1).
Over the period 2011-2025, the cumulative lost output in LMICs associated with the four NCD conditions that 
are the focus of the UN High-Level Meeting is projected to be more than US$ 7 trillion (Table 1; see also Figure 1 
for a breakdown by disease type and by country income category). The total burden is lowest in the low-income 
countries, in part because the value of lost earnings in this group is low and in part because the total population 
of this country income group is much smaller than that of the middle-income countries (which include China and 








Upper middle 0.31 2.52 1.09 1.20 5.12
Lower middle 0.09 1.07 0.44 0.26 1.85
Low income 0.02 0.17 0.06 0.05 0.31
Total of low 
and middle
0.42 3.76 1.59 1.51 7.28
Table 1: Economic Burden of NCDs, 2011-2025 (trillions of US$ in 2008)
Source: Based on The Global Economic Burden of Non-communicable Diseases 
– Prepared by the World Economic Forum and the Harvard School of Public Health (2011)











Lost output 2011-2025, by disease type 
Source: Based on The Global Economic Burden of Non-communicable Diseases –  









Lost output 2011 - 2025, by income category 
The annual loss of approximately US$ 500 billion amounts to roughly 4% of GDP for low- and middle-income 
countries in 2010. This sizable cost helps put public spending on health into perspective. In every income group, 
losses from NCDs are greater than public spending on health, assuming that inflation-adjusted levels of such 
spending remain at their 2009 levels for the period 2011-2025 (see Figure 3).4,56















































Total, low and middle income 
Low income 
Lower middle income 
Upper middle income 
Source: Based on  The Global Economic Burden of Non-communicable Diseases – Prepared by the World Economic Forum and the Harvard School of Public Health (2011) 
Source: Based on The Global Economic Burden of Non-communicable Diseases
– Prepared by the World Economic Forum and the Harvard School of Public Health (2011)

































Income group (% of world population) 
Losses from NCDs, 2011-2025 
Projected public spending on health, 2011-2025 (assuming spending remains at 2009 level) 
Source: Based on The Global Economic Burden of Non-communicable Diseases – Prepared by the World Economic Forum and the Harvard School of Public Health (2011) 
Source: Based on The Global Economic Burden of Non-communicable Diseases
– Prepared by the World Economic Forum and the Harvard School of Public Health (2011)7
Possible Solutions and Their Cost: Estimating a Global Price Tag for NCD “Best Buys”
Many interventions for prevention and control of NCDs exist. Even in the wealthiest countries, however, choices 
have to be made about which of these interventions are prioritized for implementation because resources for health 
are finite – and in most countries very limited. A number of criteria enter into such decisions, including the current 
and projected burden of disease, cost-effectiveness, fairness and feasibility of implementing interventions, and 
political considerations. 
In preparation for the UN High-Level Meeting, the WHO has identified a set of evidence-based “best buy” 
interventions that are not only highly cost-effective but also feasible and appropriate to implement within the 
constraints of the local LMIC health systems (see Table 2)6. Of course, many other interventions exist to reduce 
chronic disease at the population or individual level that, while not meeting all “best buy” criteria, may still contribute 
to a comprehensive public health response to the challenge of NCDs7,8. The WHO has developed a costing tool to 
enable countries to add or substitute interventions according to national needs or priorities.
6 Scaling up action against noncommunicable diseases: How much will it cost? 2011. Geneva, Switzerland: World Health Organization.
7 Global strategy on diet, physical activity and health. 2004. Geneva, Switzerland: World Health Organization.
8 Global strategy to reduce the harmful use of alcohol. 2010. Geneva, Switzerland: World Health Organization.
Risk factor / disease Interventions
Tobacco use •	 Tax increases
•	 Smoke-free indoor workplaces and public places
•	 Health information and warnings
•	 Bans on tobacco advertising, promotion and 
sponsorship
Harmful alcohol use •	 Tax increases
•	 Restricted access to retailed alcohol
•	 Bans on alcohol advertising
Unhealthy diet and physical inactivity •	 Reduced salt intake in food
•	 Replacement of trans fat with polyunsaturated fat
•	 Public awareness through mass media on diet and 
physical activity 
Cardiovascular disease (CVD) and diabetes •	 Counselling and multi-drug therapy for people with 
a high risk of developing heart attacks and strokes 
(including those with established CVD)
•	 Treatment of heart attacks with aspirin
Cancer •	 Hepatitis B immunization to prevent liver cancer 
(already scaled up)
•	 Screening and treatment of pre-cancerous lesions 
to prevent cervical cancer
Table 2: “Best Buy” Interventions8
Box 2:  Estimating the cost of scaling up chronic disease interventions
•	 Analysis was performed on a group of 42 low- and middle-income countries (with populations in excess of 
20 million) that account for 90% of the non-communicable disease burden in developing regions of the world. 
Upward adjustments were made from this set to derive estimates for all low- and middle-income countries.
•	 The period of scaling-up was set at 2011-2025 to achieve desired levels of treatment coverage (80%). Full 
implementation of population-based strategies would occur more rapidly (after approximately five-six years). 
•	 Key data sources included UN Population Division statistics, the WHO Global Burden of Disease and risk 
factor surveillance estimates, international treatment guidelines and cost databases.






























"Best buy" population-based interventions for NCD risk factors  (tobacco, alcohol, diet, physical activity) 
"Best buy" individual-based interventions for NCDs (cardiovascular disease, diabetes, cancer) 
Source: Scaling up action against noncommunicable diseases: How much will it cost? – Prepared by the World Health Organization (2011) 
 
The total cost of implementing the full set of “best buy” interventions across all LMICs over this period is estimated 
to be US$ 170 billion, at an average of US$ 11.4 billion per year (Figure 4). This amounts to an annual per capita 
investment of under US$ 1 in low-income countries, US$ 1.50 in lower middle-income and US$ 3 in upper middle-
income countries. When considered in terms of overall health spending, these costs constitute only a tiny portion 
of total health spending – 4% in low-income countries, 2% in lower middle-income countries and less than 1% in 
upper middle-income countries.  
As shown in Figure 4, population-based measures that address tobacco and harmful alcohol use, as well as 
unhealthy diet and physical inactivity, account for a very small fraction of the total price tag (US$ 2 billion per year – 
less than US$ 0.40 per person).10
9 Scaling up action against noncommunicable diseases: How much will it cost? 2011. Geneva, Switzerland: World Health Organization. 
10 Lower costs in the first year of scale-up reflect current screening and treatment coverage levels (<10%).
Source: Scaling up action against noncommunicable diseases: How much will it cost? – Prepared by the World Health Organization (2011)
The identified set of strategies form a basis for analysing costs of scaled-up implementation in the LMICs through 
2025 (see Box 2)9.9
10 Lower costs in the first year of scale-up reflect current screening and treatment coverage levels (<10%).
11 Asaria, P., Chisholm, D., Mathers, C. et al. “Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control 
tobacco use” in Lancet, 2007, 370: 2044-2053.
12 Lim, S., Gaziano, T., Gakidou E. et al. “Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health 
effects and costs” in Lancet, 2007, 370: 1954-1962.
13 The Global Burden of Disease. 2004. Update 2008. Geneva, Switzerland: World Health Organization.
Potential Benefits of Taking Action: Combined Conclusions
What can be expected in return for these proposed investments? In health terms, the primary benefit is a reduction 
in premature mortality due to NCDs. Previous studies have found that implementing a specific set of NCD “best 
buys” in 23 large LMICs could prevent 30 million premature deaths from 2006-2015 or an average of 3 million per 
year (Figure 5)11, 12.  
Total deaths in LMICs due to the four NCDs that are the focus of the UN High Level Meeting amounted to 23.7 
million in 200413, which indicates that at least 10-15% of premature deaths could be successfully averted through 
the scaled-up implementation of a core intervention package (i.e., 3 million out of 23.7 million).
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CVD drug therapy 
Tobacco control 
Salt reduction 
Source: Scaling up action against noncommunicable diseases: How much will it cost? – Prepared by the World Health Organization (2011) 
 
Source: Scaling up action against noncommunicable diseases: How much will it cost? – Prepared by the World Health Organization (2011)
Figure 5: Avoidable deaths from a scaled-up chronic disease intervention package in 23 low- and 
middle-income countries (2006-2015)10
Cardiovascular disease
(ischaemic heart disease and 
stroke)
Cumulative figure for 2011-2025
(US$ billions)
Average annual figure for 2011-
2025 (US$ billions)
Cost of “best buy” interventions
(scaled-up response)
120 8
Projected economic benefit 
(10% reduction in CVD mortality)
377 25
Table 3: Cost and Benefits of Scaling Up  “Best Buy” Interventions for Cardiovascular Disease, 2011-
2025 (US$ billions)
In macroeconomic terms, the key benefits derived from these health improvements include the restored or 
continued ability of individuals to lead flourishing lives and to participate actively in the workplace. For example, a 
10% reduction in the mortality rate due to ischaemic heart disease and stroke would reduce economic losses in 
LMICs by an estimated US$ 377 billion over the period 2011-2025 – an average of US$ 25 billion per year. This 
sum is approximately three times the yearly cost of scaling up “best buy” interventions for cardiovascular disease 
(see Table 3).
Realizing these benefits will require firm commitments of resources and capabilities, not only by governments 
but also by civil society, development agencies, the private sector and academia. Governments and international 
organizations can provide leadership, establish necessary frameworks, create infrastructure and create health 
policies. Academia can contribute scientific insights and expertise. NGOs and civil society can raise the profile of 
NCDs and support implementation and action on the ground. The private sector can leverage core business skills, 
networks and funds to access target populations and offer innovative products and solutions. 
Collaboration among these partners will allow societies to capitalize on individual strengths and realize benefits 
beyond the reach of any single entity to ensure that communities have the necessary resources to manage the 
growing burden of NCDs.11
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